News
Biomarkers could determine the need for chemotherapy in young patients with ER+ breast cancer
New research from Yale Cancer Center identified that two simple biomarkers, immune cells and estrogen receptor levels, could differentiate which young women with ER+ breast cancer need chemotherapy to improve their survival, and which only need a monthly injection of endocrine therapy to suppress ovarian function.